SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders closely monitor the government shutdown vote, anticipating market impacts. Community discussions revolve around whether the reopening is already priced in, while some express concern over potentially delayed economic data. There's also chatter about the possible release of Epstein files and how that may impact the markets.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders react to the House passing a bill to end the government shutdown and anticipate Trump's signature. While some community members are optimistic about a potential rally, others believe the news is already priced in and are watching for a "sell the news" event or a sector rotation. There is also a lot of talk about a possible AI bubble and the potential impact of delayed economic data.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions surrounding newly released Epstein emails and Trump's alleged connections, sparking renewed scrutiny and debate. Community members are actively discussing the implications of these revelations, with some questioning Trump's past associations and others defending him against the allegations. The stock's performance is being closely watched in light of these developments.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending amidst mixed sentiment regarding its future and the impact of the recently launched Janction (JCT) token; some community members express concerns about resource allocation between the two projects, while others view JCT as beneficial to the broader Jasmy ecosystem and driving demand. Discussions also include technical analysis, price predictions, and frustration with the token's performance in a fluctuating market.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending downwards as investors discuss an upcoming lockup expiration, potentially leading to increased selling pressure. Despite some bullish sentiment and Cathie Wood's ARK Invest adding shares, the community is wary of potential insider selling. Discussions also involve the broader stablecoin market and regulatory landscape, with some comparing CRCL to other hyped IPOs.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to activist investor Shah Capital pushing for the company's sale, citing management's "profound lack of competence" and expressing frustration over Novavax's minuscule COVID vaccine market share. The community is echoing Shah's concerns, criticizing CEO John Jacobs' leadership and advocating for a sale to a larger pharmaceutical company. Discussions center on whether a sale is the best path forward, given the company's struggles in the competitive vaccine market.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as investors discuss the company's upcoming presentation at the Inflammatory Skin Disease Summit and a confirmed FDA meeting in December, both seen as potential catalysts. Bullish sentiment is fueled by significant institutional ownership and recent data suggesting a best-in-class profile for their drug, SLK, despite a recent public offering.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as community members discuss its potential as the next Palantir, fueled by a recent acquisition and Q3 earnings. Bullish sentiment is further driven by the anticipation of government contracts, particularly related to border security, following the potential government reopening. Discussions also focus on high short interest and potential for a short squeeze.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending due to a potential short squeeze, fueled by an upcoming warrant distribution and the CEO's recent stock purchase, signaling strong confidence. The community is actively discussing the possibility of a significant squeeze, drawing comparisons to other high-profile situations and highlighting the warrant issuance as a key catalyst for short covering. Amidst this, some traders have pointed to potentially dilutive effects to the stock price.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney ($DIS) is trending due to upcoming earnings, with community members actively discussing potential catalysts and market sentiment. Bullish sentiment is fueled by the possibility of a solid earnings beat and positive momentum, while others express concerns about various challenges and the stock's historical performance. Discussions also include Disney's streaming strategy, theme park performance, and broader market context, as well as some chatter about a dispute with Youtube TV.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to EMA on human medicines, which the agency uses to approve or reject a drug.</li><li>Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December.&nbsp;</li><li>If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.</li></ul>Shares of Anavex Life Sciences (AVXL) were in the spotlight on Monday as retail investors contemplated the possibilities of a positive take from a European Medicines Agency (EMA) committee for the company’s Alzheimer’s drug Blarcamesine.The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to the agency on human medicines, which the agency uses to approve or reject a drug. On Monday, CHMP <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-10-13-november-2025_en.pdf">included</a> Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13. The oral explanation for Blarcamesine is scheduled for Nov. 11, 2025, at 2:00 p.m.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>A Stocktwits user is keenly awaiting the statement from Anavex.<stembedurl>https://stocktwits.com/DipperDoo/message/635619033</stembedurl>Another user expressed hope that the committee would be convinced of the drug’s importance following the oral presentation.<stembedurl>https://stocktwits.com/Cresskill198/message/635618141</stembedurl>AVXL shares were down 9% at the time of writing. On Stocktwits, overall retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/57;" src="data:image/png;base64,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" width="587" height="57" alt="AVXL's Sentiment Meter and Message Volume as of 1:06 p.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>AVXL's Sentiment Meter and Message Volume as of 1:06 p.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Anavex’s Application</h2>Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.Last month, Spirit of the Coast Analytics <a href="https://stocktwits.com/news-articles/markets/equity/anavex-life-sciences-stock-sparks-retail-banter-on-hopes-of-ema-conditional-nod-for-alzheimer-s-drug-big-pharma-tie-up/cLGP67oR3po">noted</a> that Blarcamesine’s existing Phase 2b/3 data, while limited in sample size and missing one co-primary endpoint, showed statistically strong results and sustained efficacy over 192 weeks in long-term studies. According to the analyst, the company is “likely” positioned for approval by the EMA in Q4 2025 or Q1 2026. &nbsp;AVXL stock is down by 38% this year and by about 28% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ifrx-stock-soars-pre-market-after-experimental-drug-shows-promise-in-treating-chronic-skin-diseases/cLPcS62RE2E">IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee

On Monday, CHMP included Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13.

Equity

On Monday, CHMP included Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13.


<ul class="summary-bullets"><li>The pharma major now expects adjusted earnings in the range of $3.00 to $3.15 for the full year.&nbsp;</li><li>Q3 revenue totaled $16.7 billion, down 6% year-over-year due to a decline in COVID-19 product revenues.</li><li>Revenues from the company’s anticoagulant Eliquis, however, rose 25% to $2.02 billion, driven by higher demand.&nbsp; &nbsp;</li></ul>Pfizer Inc. (PFE) on Tuesday raised its full-year adjusted earnings guidance to a range of $3.00 to $3.15, citing continued confidence in the business and progress with ongoing cost improvement initiatives.The company was previously expecting adjusted earnings in the range of $2.90 to $3.10 per share. Pfizer is now on track to deliver approximately $7.2 billion in overall anticipated net cost savings by the end of 2027, driven by cost improvement initiatives announced previously.The pharma major also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://s206.q4cdn.com/795948973/files/doc_financials/2025/q3/Q3-2025-PFE-Earnings-Release-FINAL.pdf">reaffirmed</a> its full-year revenue guidance of $61.0 billion to $64.0 billion.<h2 class="st-heading-2">Q3 Earnings &nbsp;</h2>For the third quarter, the company reported adjusted earnings per share of $0.87, down from the $1.06 reported in the corresponding period of 2024, but above an analyst estimate of $0.64, according to data from Fiscal AI.Revenue for the three months through the end of September totaled $16.7 billion, down 6% year-over-year due to a decline in COVID-19 product revenues, but above the estimated $16.5 billion.The company’s Paxlovid, an antiviral medication used to treat COVID-19, and its anti-COVID-19 vaccine Comirnaty, saw revenues in the quarter down by 55% and 19%, respectively, on a total basis.Revenues from the company’s anticoagulant Eliquis, however, rose 25% to $2.02 billion, driven by higher demand. Other drugs to see revenue growth in the quarter include the heart disease drug Vyndaqel, which experienced a 10% increase to $ 1.59 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded 1% lower in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.PFE stock is down 7% this year and approximately 11% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-reportedly-drop-10-percent-in-october/cL28BCjR3CD">Tesla’s China-Made EV Sales Reportedly Drop 10% In October, Lowest Since May</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Optimism has also been recently driven by Pfizer’s solid quarterly performance.

Pfizer Raises Full-Year Earnings Guidance, Q3 Numbers Beat Street Estimates

The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027. 

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025

The company has increased its adjusted revenue outlook to a range of approximately $47.5 billion to $48.0 billion, up from a previous range of roughly $46.5 billion to $47.5 billion.

<ul class="summary-bullets"><li>The study was designed to study the efficacy and safety of Encaleret and enrolled 70 adults with ADH1.</li><li>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.</li><li>The company now plans to submit a new drug application to the U.S. Food and Drug Administration in the first half of 2026. &nbsp;</li></ul>Shares of BridgeBio Pharma, Inc. (BBIO) rose 4% on Wednesday afternoon after the company announced that its late-stage study of Encaleret in patients with autosomal dominant hypocalcemia type 1 met all primary and key secondary endpoints.This marks the company’s second positive trial result announcement this week. The Encaleret<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.bridgebio.com/news/news-details/2025/BridgeBio-Reports-Positive-Phase-3-Topline-Results-for-Encaleret-in-Patients-with-Autosomal-Dominant-Hypocalcemia-Type-1/default.aspx"> study</a> was designed to study the efficacy and safety of the drug and enrolled 70 adults with ADH1– autosomal dominant hypocalcemia type 1 – a genetic disorder that causes low blood calcium levels, a condition known as hypocalcemia. Symptoms, which can range from none to severe, include muscle spasms, cramps, tingling sensations, and, in severe cases, seizures.<h2 class="st-heading-2">Trial Outcomes</h2>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment compared to 4% when on conventional therapy, the company said. Furthermore, the drug was well-tolerated, the company noted.The company now plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) in the first half of 2026, followed by an application to the European Medicines Agency.The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026. The trial in pediatric ADH1 is slated for the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BBIO">BBIO stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user termed the news great but expressed disappointment that the stock didn't rally further.<stembedurl>https://stocktwits.com/SugarSlim/message/634124724</stembedurl>Wednesday’s results come after the company <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">announced</a> on Monday that limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months.BBIO stock is up by 145% this year and by about 175% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results 

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026.

<ul class="summary-bullets"><li>Trian Fund Management said it beneficially owns 20.4% of the outstanding ordinary shares of Janus Henderson.</li><li>The per-share price of $46 represents a 10.5% premium over the Oct. 24, 2025, closing price.</li><li>Trian said a mix of third-party equity and debt financing would fund the transaction consideration.</li></ul>Trian Fund Management, Nelson Peltz’s asset management firm, said that the company, along with General Catalyst Group Management, has submitted a non-binding proposal to buy the rest of Janus Henderson Group (JHG) that it does not own for $46.00 per share in cash.U.S.-listed shares of Janus Henderson jumped 18% in early trading on Monday. Trian said that, pursuant to the proposal, a newly formed entity on behalf of General Catalyst and Trian Fund would acquire all of the shares of Janus Henderson not currently owned by Trian.Trian said it beneficially owns 20.4% of the outstanding ordinary shares of Janus Henderson.<h2 class="st-heading-2">Price Premium</h2>The per-share price of $46 represents a 10.5% premium over the Oct. 24, 2025, closing price. Trian said that the proposed transaction would derisk an investment that it believes is highly sensitive to capital market and geopolitical dynamics.Trian noted that the per-share price represents an over 56% premium to where the shares traded as recently as this past April, when capital market conditions were less favorable.“When Trian first disclosed its investment in the company in October 2020, the shares were trading at $21.60 per Share, and the company was consistently experiencing outflows in the mid-single digits,” Peltz said in an email to the board of Janus Henderson.“Since that time, the company’s board of directors and management team (led by CEO Ali Dibadj) have achieved a highly successful operational turnaround of the company’s business, which today consistently generates positive net inflows while enjoying mid-30% operating margins,” he added.<h2 class="st-heading-2">Financing Details Of The Proposed Transaction</h2>The transaction consideration would be funded by a mix of equity and debt financing from third parties, including limited partners of Trian and General Catalyst, as well as their affiliated funds, Trian said.“It is our expectation that the board will appoint a special committee of independent, disinterested directors (the “Special Committee”) to consider the proposed transaction and make a recommendation to the Board,” Peltz said.Retail sentiment on Janus Henderson remained unchanged in the ‘bullish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/JHG">Shares of Janus Henderson</a> have gained nearly 16% this year and have jumped over 21% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/organon-ceo-kevin-ali-resigns-audit-probe-into-wholesaler-sales-practices/cLG0eYHR3M8">Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices</a>

Nelson Peltz and Elon Musk attend the Premiere of "Lola" at Regency Bruin Theatre on February 03, 2024 in Los Angeles, California.

JHG Stock Rockets 15% Pre-Market After Receiving A Non-Binding Proposal For $46 Per Share

Trian Fund Management said it beneficially owns 20.4% of the outstanding ordinary shares of Janus Henderson.

<ul class="summary-bullets"><li>Organon said that the investigation found that certain wholesalers in the United States were asked to buy more Nexplanon than they needed.</li><li>The company said that the investigation found these sales represented less than 1% of its consolidated revenue for the year ended Dec. 31, 2022, or Dec. 31, 2024, as applicable.</li><li>Organon said that the board of directors has appointed the company’s Executive Vice President and Head of Manufacturing &amp; Supply, Joseph Morrissey, as its Interim Chief Executive Officer.</li></ul>Organon (OGN) on Monday announced the resignation of Kevin Ali as Chief Executive Officer and a member of the board, in connection with an Audit Committee investigation into sales to wholesalers.Shares of Organon were down nearly 22% in early trading. The company said that after concerns regarding its wholesaler sales practices for its Nexplanon product were brought to the board’s attention, the Audit Committee oversaw an independent, internal investigation into the matter.Organon said that the investigation found that certain wholesalers in the United States were asked to buy more Nexplanon than they needed at the end of the fourth quarter of 2022, the third and fourth quarters of 2024, and the first, second and third quarters of 2025.Retail sentiment on Organon remained unchanged in the ‘bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Investigation Details</h2>Organon said that the investigation found that certain wholesalers in the United States were asked to buy more Nexplanon than they needed at the end of the fourth quarter of 2022, the third and fourth quarters of 2024, and the first, second, and third quarters of 2025.The company said that the investigation found these sales represented less than 1% of its consolidated revenue for the year ended Dec. 31, 2022, or Dec. 31, 2024, as applicable, but enabled Organon to meet guidance or certain external revenue expectations.Organon noted that the board determined that these wholesaler sales practices were improper and certain of the company’s prior statements were inaccurate or incomplete.“While the findings to date do not necessitate a restatement or revision to any previously issued financial statements, the company is taking remedial actions to improve its financial controls and address any material weaknesses,” Organon said.In connection with the investigation, the company said that it terminated the employment of its Head of U.S. Commercial &amp; Government Affairs, and there has been no finding that the company’s Chief Financial Officer was aware of the improper wholesaler sales practices.<h2 class="st-heading-2">Interim CEO</h2>Organon said that the Board of Directors has appointed the company’s Executive Vice President and Head of Manufacturing &amp; Supply, Joseph Morrissey, as its Interim Chief Executive Officer.The company said Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Morrissey in his new role. The Board is initiating a search for a permanent CEO, including both internal and external candidates, Organon said.<a href="https://stocktwits.com/symbol/OGN">Shares of Organon</a> have declined nearly 48% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/albemarle-to-sell-majority-stake-in-ketjen-s-refining-business-to-kps/cLG0IEGR3MV">Albemarle To Sell Majority Stake In Ketjen’s Refining Catalyst Business To KPS Capital Partners</a>

In this photo illustration, an ORGANON logo is seen displayed on a smartphone and in the background.

Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices

Organon said that the investigation found that certain wholesalers in the United States were asked to buy more Nexplanon than they needed.

<ul class="summary-bullets"><li>Albemarle also announced the sale of its entire 50% interest in the Eurecat joint venture to Axens SA.</li><li>The company said that Albemarle and KPS, through affiliates, will own about 49% and 51% of Ketjen at close, respectively.</li><li>Albemarle said that across the two transactions, it expects to receive total pre-tax proceeds of approximately $660 million.</li></ul>Albemarle Corp. (ALB) said on Monday it would sell a controlling stake in Ketjen Corporation's refining catalyst solutions business to KPS Capital Partners.The company said that Albemarle and KPS, through affiliates, will own about 49% and 51% of Ketjen at close, respectively. KPS will hold a majority of the board seats and operational control of Ketjen.Shares of Albemarle were down by more than 2% in premarket trading. The company said it would retain 100% of Ketjen Corporation's Performance Catalyst Solutions business, including its Pasadena, Texas, plant.&nbsp;The company also announced the sale of its entire 50% interest in the Eurecat joint venture to Axens SA. Albermarle noted that both transactions are expected to be completed in the first half of 2026.<h2 class="st-heading-2">Proceeds From The Transactions</h2>The firm said that across the two transactions, it expects to receive total pre-tax proceeds of approximately $660 million, while also retaining about a 49% stake in Ketjen. The company expects to use these proceeds for debt reduction and other general corporate purposes.Retail sentiment on <a href="https://stocktwits.com/symbol/ALB">Albemarle</a> remained unchanged in the ‘bearish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Executive View On Stake Sale</h2>CEO of Albemarle Kent Masters said that these transactions align with Albemarle's strategic priorities to focus on its core businesses and competencies, improve financial flexibility, and streamline operations.“Albemarle's retained stake in Ketjen highlights our belief in the business' earnings growth and value creation potential under KPS' direction, and we look forward to partnering with them in driving Ketjen's next phase of growth,” said Masters.Shares of Albemarle have gained nearly 23% this year and about 8% over the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-sotherly-hotels-stock-surge-a-whopping-130-today/cLG0Eu2R3Mi">Why Did Sotherly Hotels' Stock Surge A Whopping 130% Today?</a>

 In this photo illustration, a smartphone displays the logo of Albemarle Corporation (NYSE: ALB). 

Albemarle To Sell Majority Stake In Ketjen’s Refining Catalyst Business To KPS Capital Partners

The company said that Albemarle and KPS, through affiliates, will own about 49% and 51% of Ketjen at close, respectively.

<ul class="summary-bullets"><li>Roger Connor is leaving the role to return to the U.K. to be closer to family, according to a Bloomberg report on Thursday, citing an internal memo.</li><li>Finance executive Ben Eklo will take over as the unit’s CFO starting November 1, the report added.&nbsp;</li><li>Connor’s exit marks the latest management overhaul at the company this year. &nbsp;</li></ul>UnitedHealth Group’s (UNH) Optum unit’s CFO, Roger Connor, is reportedly leaving the role less than six months into the role.According to a Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-23/unitedhealth-s-optum-unit-gets-second-new-cfo-in-six-months">report</a> on Thursday, citing an internal memo, Connor is leaving the role to return to the U.K. to be closer to family. Finance executive Ben Eklo will take over as the unit’s CFO starting November 1, the report added. Eklo has been with UnitedHealth for 18 years.Connor, however, will stay on at the company through April to ensure a transition, the memo reportedly said. He was appointed Optum CEO in May. The memo also described several other changes in finance roles in the company’s business units, including at Optum Health and for UnitedHealthcare’s government insurance plans, Bloomberg added.<h2 class="st-heading-2">Optum’s Significance</h2>UnitedHealth’s Optum division includes its pharmacy benefits business, a portfolio of medical clinics and in-home care programs, and a data and technology unit.In July, the company said it expects total Optum revenue of $266 billion to $267.5 billion and operating earnings of $12.55 billion to $12.85 billion for the full year 2025. In the three months through the end of June, the division reported revenue of $67.2 billion and earnings from operations of $3.1 billion.<h2 class="st-heading-2">Management Shake-Ups This Year</h2>Connor’s exit marks the latest management overhaul at UNH this year. Andrew Witty withdrew from his CEO role in May, citing personal reasons, and was <a href="https://stocktwits.com/news-articles/markets/equity/unitedhealth-shareholder-propoes-distinct-chairman-chief-executive-roles-report/chCuNwfR3Qa">replaced</a> by Stephen Hemsley. The company also <a href="https://stocktwits.com/news-articles/markets/equity/united-health-s-cfo-shake-up-doesn-t-deter-retail-bulls-traders-call-stock-a-2018-level-opportunity/chr3k1VRdGi">named</a> Wayne DeVeydt as CFO in July, replacing John F. Rex.The management shakeups follow other crises at the insurance company. In July, the insurer issued fresh guidance for full-year revenue of $445.5 billion to $448.0 billion and adjusted earnings of at least $16.00 per share, after suspending its previous outlook in May due to higher medical costs. The company had previously forecast adjusted profit of $29.50 to $30.00 per share, nearly double its latest forecast.<a href="https://stocktwits.com/symbol/UNH">UNH shares</a> fell 1% on Thursday afternoon at the time of writing. On Stocktwits, retail sentiment around UNH rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:622/57;" src="data:image/png;base64,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" width="622" height="57"><figcaption>UNH's Sentiment Meter and Message Volume as of 12:18 p.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>UNH stock is down by 29% this year and by 36% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/intelligent-bio-solutions-stock-rises-on-new-contract-for-drug-testing-technology/cLG4mupR3rX">Intelligent Bio Solutions Stock Rises On New Contract For Drug Testing Technology</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of UnitedHealth Group Incorporated. (Photo illustration by Cheng Xin/Getty Images)

 UnitedHealth’s Optum CFO Reportedly Exits In Less Than Six Months Into The Role

Roger Connor is leaving the role to return to the U.K. to be closer to family, according to a Bloomberg report on Thursday, citing an internal memo.

<ul class="summary-bullets"><li>Applied Digital said that this was a nearly 15-year lease agreement to deliver 200 MW of critical IT capacity at Polaris Forge 2.</li><li>The company noted that the 200 MW&nbsp;capacity would support the hyperscaler’s artificial intelligence (AI) and high-performance compute (HPC) infrastructure.&nbsp;</li><li>Applied Digital’s total leased capacity with two hyperscalers across its Polaris Forge 1 and Polaris Forge 2 campuses in North Dakota has now reached 600 MW.</li></ul>Applied Digital (APLD) shares jumped nearly 7% before the bell on Wednesday after the company announced a $5 billion AI factory lease with a U.S.-based investment-grade hyperscaler at Polaris Forge 2 campus, currently under construction near Harwood, North Dakota.&nbsp;The company said this was a nearly 15-year lease agreement to deliver 200 megawatts (MW) of critical IT capacity at Polaris Forge 2 to support the hyperscaler’s artificial intelligence (AI) and high-performance compute (HPC) infrastructure.&nbsp;Retail sentiment on <a href="https://stocktwits.com/symbol/APLD">Applied Digital</a> improved to ‘bullish’ from ‘neutral’ territory compared to a day ago, with message volumes at ‘normal’ levels, according to data from Stocktwits.<h2 class="st-heading-2">What To Know About Applied Digital’s AI Factory Lease</h2>Applied Digital said the Hyperscaler also holds a first right of refusal for an additional 800 MW of critical IT, representing the full expansion potential of the 1-gigawatt (GW) Polaris Forge 2 Campus.The company said that with this agreement, Applied Digital’s total leased capacity with the two hyperscalers across its Polaris Forge 1 and Polaris Forge 2 campuses in North Dakota has now reached 600 MW.<h2 class="st-heading-2">Polaris Forge 2</h2>The company said that the Polaris Forge 2 spans more than 900 acres and is engineered to deliver efficiency with a projected power usage effectiveness of 1.18 and near-zero water consumption.Applied Digital stated that the initial 200 MW will be phased across two buildings, with operations expected to begin in 2026 and reach full capacity by 2027. The campus is designed for future expansion.This follows Applied Digital's announcement of an additional 150MW lease with CoreWeave at its Polaris Forge 1 Campus, as well as a $5.0 billion AI infrastructure partnership with Macquarie Asset Management.Shares of Applied Digital have gained 316% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nhl-signs-multiyear-licensing-deals-with-kalshi-polymarket-report/cLG5edGR3qd">NHL Signs Multiyear Licensing Deals With Kalshi, Polymarket: Report</a>

In this photo illustration, a smartphone displays the logo of Applied Digital Corporation (NASDAQ: APLD) on July 28, 2025, in Chongqing, China. 

Applied Digital Stock Soars 7% Pre-Market On $5B AI Factory Lease With US Hyperscaler

Applied Digital said that this was a nearly 15-year lease agreement to deliver 200 MW of critical IT capacity at Polaris Forge 2.

Hillenbrand (HI) announced on Wednesday that it has entered into a definitive agreement to be acquired by an affiliate of Lone Star Funds in an all-cash transaction valuing the company at $3.8 billion.Shares of Hillenbrand jumped nearly 19% in premarket trading after the company said it would be bought for $32.00 per share, which represents a premium of approximately 37% over Hillenbrand's unaffected closing share price of $23.43 on August 12. The transaction is expected to close by the end of the first quarter of calendar year 2026.Retail sentiment on <a href="https://stocktwits.com/symbol/HI">Hillenbrand</a> improved to ‘neutral’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘normal’ levels, according to data from Stocktwits.&nbsp;“The Board carefully reviewed a range of potential strategic alternatives, including interest from a number of parties, and determined that this transaction is in the best interest of Hillenbrand and its shareholders,” said Helen Cornell, Chairperson of the Board of Directors.Hillenbrand said that once the deal is closed, it will become a privately held company, and the company’s shares will no longer trade on the New York Stock Exchange. Shares of the company traded nearly 3% higher in Wednesday’s pre-market session.The company said during its fourth-quarter results that it would not be issuing financial guidance for fiscal year 2026.Hillenbrand is known for providing processing equipment and solutions to customers around the world through its Advanced Process Solutions and Molding Technology Solutions segments.&nbsp;Shares of Hillenbrand have declined nearly 14% this year and have fallen 6% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-dollar-tree-stock-rising-today/ch6nw5IR3NW">Why Is Dollar Tree Stock Rising Today?</a>

Hillenbrand To Go Private In Nearly $4B Deal With Affiliate Of Lone Star Funds

The company will be bought for $32.00 per share, which represents a premium of approximately 37% over Hillenbrand's unaffected closing share price on August 12.

iShares Trust - iShares ESG Aware 60/40 Balanced Allocation ETF

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$35.57
Prev Close	$35.56
Open	$35.63
Dividend Yield	N/A
50-Day Moving Average	$35.03
Beta	N/A
Avg. Volume	1,695.57
PE Ratio	N/A

52-Week High	$35.77
52-Week Low	$28.94
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

EAOR
iShares ESG Aware 60/40 Balanced Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Latest EAOR News

EAORiShares ESG Aware 60/40 Balanced Allocation ETF